



Oxygen-15

Revised: October 15, 2023.

CASRN: 13982-43-9

Drug Levels and Effects

Summary of Use during Lactation

Information in this record refers to the use of oxygen-15 radiopharmaceuticals as diagnostic agents. United States and international authorities state that breastfeeding need not be interrupted after administration of radiopharmaceuticals containing oxygen-15.[1,2]

Drug Levels

Oxygen 15 decays by positron emission with a half-life of 2.04 minutes.[2]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Mattsson S, Johansson L, Leide Svegborn S, et al. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. ICRP Publication 128. Annex D. Recommendations on breast-feeding interruptions. Ann ICRP 2015;44 (2 Suppl):7-321.
2. Dilsizian V, Metter D, Palestro C, Zanzonico P. Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Material. Final report submitted: January 31, 2019. 2019. Available at: <https://www.nrc.gov/docs/ML1903/ML19038A498.pdf>

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Substance Identification

Substance Name

Oxygen-15

CAS Registry Number

13982-43-9

Drug Class

Breast Feeding

Lactation

Milk, Human

Radiopharmaceuticals

Oxygen Radioisotopes

Diagnostic Agents